SpectrumX reaches partnership agreement on human volunteer study for ground-breaking respiratory infection drug candidate SPX-001
Start-up agreement is major step forward in readiness to conduct Phase 1b clinical trial of Company’s HOCl-based respiratory infection drug candidate, SPX-001 Start-up agreement is major step forward in readiness to conduct Phase 1b clinical trial of Company’s HOCl-based respiratory infection drug candidate, SPX-001 Partner and SpectrumX will align on detailed clinical trial protocol to […]
SpectrumX announces significant updates at Knutsford production facility
Critical upgrades allow the Company to produce SPC-069 drug substance for clinical trials Other new additions to the facility include dedicated quality control room, microbiology laboratory and office space Knutsford, United Kingdom– SpectrumX, a UK-based healthcare and pharmaceutical company, announced today that recent upgrades at its state-of-the-art production facility in Knutsford, Cheshire, will allow the […]
SpectrumX expands R&D division with appointment of microbiology team
In-house Microbiology laboratory commissioned to accelerate product range development and enhance differentiation
SpectrumX confirms scientific advice meeting with MHRA, proposed timeline for human clinical trials for ground-breaking medicine SPX-001
The Company identifies critical milestones required to commence clinical trial programme London, United Kingdom, 8 August 2022: SpectrumX, a UK-based healthcare and pharmaceutical company, is pleased to announce that is has a date for a scientific advice meeting with the UK Medicines and Healthcare products Regulatory Agency (MHRA) to discuss its human clinical trial programme. SpectrumX […]
SpectrumX confirms scientific advice meeting with MHRA, proposed timeline for human clinical trials for ground-breaking medicine SPX-001
The Company identifies critical milestones required to commence clinical trial programme
